Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06644755 · ClinicalTrials.gov registry record · Phase 1
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
A Phase 1 study of Sarcoma and Solid Tumors, sponsored by Daiichi Sankyo.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 150
- Enrollment target
- 7
- Study locations
NCT06644755 is a Phase 1 study of Sarcoma and Solid Tumors that is actively recruiting participants, run by Daiichi Sankyo. The registered enrollment target is 150 participants, below the 920-participant average among 122 other Sarcoma trials with a reported enrollment target (84% lower). The trial reports 7 study locations across 4 states.
The verdict
NCT06644755, a Phase 1 study of Sarcoma and Solid Tumors, is actively recruiting participants, sponsored by Daiichi Sankyo.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 150 participants
- Enrollment target
- 7
- Study locations
Study Summary
This 2-part study will evaluate safety, tolerability, and clinical efficacy of DS-2243a as a treatment for participants with advanced solid tumors.
Conditions Studied
Interventions
- DRUG DS-2243a
Study Locations (7)
Other
- UZ Leuven Europe Leuven - Leuven
- Centre Leon Berard - Lyon
- Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL) - Amsterdam
- Seoul National University Hospital - Seoul
Massachusetts
- Dana-Farber Cancer Institute - Boston
New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center - New York
Tennessee
- Sarah Cannon Research Institute - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2024-11-14 |
| Est. Completion | 2028-11-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06644755
The ClinicalTrials.gov registry entry for NCT06644755 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 920-participant average among 122 other Sarcoma trials with a reported enrollment target (84% lower). The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which DS-2243a is the first listed.
NCT06644755 reports 7 study locations spanning 4 distinct geographic areas - top geographies include Other, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT06644755 about?
NCT06644755 is a clinical study titled "First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors". This 2-part study will evaluate safety, tolerability, and clinical efficacy of DS-2243a as a treatment for participants with advanced solid tumors.
What is the current status of trial NCT06644755?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2024-11-14. Estimated completion is 2028-11-30.
What conditions does trial NCT06644755 study?
This clinical trial studies the following conditions: Sarcoma, Solid Tumors.
What interventions are being tested in trial NCT06644755?
The interventions under investigation include: DS-2243a (DRUG).
Who is sponsoring clinical trial NCT06644755?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06644755 being conducted?
This trial has 7 study locations across Massachusetts, New York, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Palbociclib and Pembrolizumab in Sarcoma
RECRUITING · Phase 1
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
-
Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
RECRUITING · Phase 1
-
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.